
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| ||||||||||||||||||||||||||||||||||||||||||||||||||
Perspective |
Author's Affiliation: Department of Medicine and Ireland Cancer Center, Case Western Reserve University School of Medicine and Case Medical Center, Cleveland, Ohio and Howard Hughes Medical Institute, Chevy Chase, Maryland
Correspondence: Requests for reprints: Sanford D. Markowitz, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH 44106. Phone: 216-368-1976; Fax: 216-368-8928; E-mail: sxm10{at}cwru.edu.
Abstract
The past 10 to 15 years have witnessed major advances in our understanding of polyunsaturated fatty acid metabolism involving synthesis, activity, and degradation of prostaglandin (PG), especially prostaglandin E2 (PGE2), in neoplasia, in particular colorectal neoplasia. Little is known, however, about the role of PG transport in these processes. The flow of PGs in and out of colorectal cells involves highly coordinated activities of PG transporters that become highly dysregulated in colorectal neoplasia. Recent work by various investigators supports key components of this flow for novel molecular-targeted approaches to prevent or treat colorectal neoplasia.
Key Article
Cancer Prevention Research 2008 0: 194062070.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |